Susquehanna International Group, LLP Nuvalent, Inc. Call Options Transaction History

Susquehanna International Group, LLP

7 transactions

Quarter	Operation	Price Per call	calls change	calls Held
Q3 2024 Nov 14, 2024	SELL	$67.44 - $112.17 $15 Million - $25 Million	-222,700 Reduced 59.99%	148,500 $15.2 Million
Q2 2024 Aug 15, 2024	SELL	$62.76 - $81.61 $11.7 Million - $15.2 Million	-186,600 Reduced 33.45%	371,200 $28.2 Million
Q1 2024 May 07, 2024	BUY	$72.35 - $88.99 $20.5 Million - $25.3 Million	283,800 Added 103.58%	557,800 $41.9 Million
Q4 2023 Feb 14, 2024	BUY	$42.42 - $80.28 $9.71 Million - $18.4 Million	229,000 Added 508.89%	274,000 $20.2 Million
Q3 2023 Nov 14, 2023	BUY	$39.12 - $49.85 $1.76 Million - $2.24 Million	45,000 New	45,000 $2.07 Million
Q1 2023 May 16, 2023	BUY	$25.42 - $33.52 $1.84 Million - $2.43 Million	72,400 Added 48.59%	221,400 $5.78 Million
Q4 2022 Feb 14, 2023	BUY	$18.46 - $36.37 $2.75 Million - $5.42 Million	149,000 New	149,000 $4.44 Million

209

59.5M

450K

619K

Ticker NUVL
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 42,977,800
Market Cap $3.73B
Description
Nuvalent, Inc., a clinical stage biopharmaceutical company, develops therapies for patients with cancer. Its lead product candidates are NVL-520, a brain-penetrant ROS1-selective inhibitor to inhibit ROS1 fusions that express the normal ROS1 kinase domain without any drug-resistant mutations and remain active in the presence of mutations conferr...

Get notified when there are updates to the investment portfolio of Susquehanna International Group, LLP, based on Form 13F filings with the SEC.

Stay updated on Susquehanna International Group, LLP with notifications on news.